ClinicalTrials.gg
CompletedNCT02714972PHM3Updated Oct 15, 2026Results posted

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents

An interventional study of Hyperglycemia Minimization Algorithm in Type 1 Diabetes, Hypoglycemia and Hyperglycemia, sponsored by Jaeb Center for Health Research. Completed at 2 sites in United States. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Jaeb Center for Health Research · Not applicable, Interventional, and Prevention

How we know

Updated Oct 15, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
6 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Jaeb Center for Health Research.

Enrollment
21st of 29
35 · median 74
Started
2016
with 1 other
No phase
10 of 36
1 open now
Registered
25th of 36
by date

Among the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, this one is the 21st largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2016, is one of 10 with no phase, and was the 25th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 6 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Diabetes Mellitus, Type 1 by Jaeb Center for Health Research, or all of them as a file.
02

Study summary

Objective: to gain experience in children and younger adolescents with in-home use of an algorithm that will dose insulin to minimize projected hyperglycemia overnight in addition to suspending the pump if hypoglycemia is projected overnight and to obtain feasibility, safety, and initial efficacy data

Study Design: randomized controlled trial, with randomization on a night level within subject Patient Population: Youth 6.0 - \<15 years old with type 1 diabetes treated with daily insulin therapy for at least one year and an insulin infusion pump for at least 6 months who have HbA1c \< 10.0%.

Sample Size: 30 subjects

Study Duration and Visit Schedule: duration approximately 3 months, with preliminary run-in activities followed by up to 90 days spent in clinical trial phase of study; clinic visits at enrollment, following CGM and system assessment run-in phases, at start of clinical trial phase, at 21-day point of clinical trial phase, and after 42 nights of successful system use

Major Efficacy Outcomes:

  • Primary: time in range (70-180 mg/dl, 3.9-10.0 mmol/L) overnight.
  • Secondary: time spent in hypoglycemia (\<70 mg/dl, 3.9 mmol/L) and time spent in hyperglycemia (>180 mg/dl, 10.0 mmol/L) overnight.

Major Safety Outcomes: CGM measures of hypo- and hyperglycemia, including morning blood glucose and mean overnight sensor glucose; adverse events including severe hypoglycemia and diabetic ketoacidosis

Read the detailed description

Subjects who are eligible for the clinical trial initially will use a Veo insulin pump and Enlite CGM sensor at home for a minimum of 6 days/week over a 2-week period to verify that the subject is able to use the CGM and insert sensors.

The first 10 subjects enrolled will be 11 to \<15 years of age and will participate in an Algorithm Assessment Phase of approximately 10 nights of system use each with PLGS and Hyper Minimization active. Results of the approximate 100 nights will be reviewed with the study DSMB to assess safety and determine whether any adjustments to the algorithm parameters are needed. If adjustments are needed, the Algorithm Assessment Phase will be repeated with the same age restriction, using the same 10 subjects if possible. If no adjustments are needed and the DSMB judges it safe to continue the study, enrollment will continue across the full 6 to \<15 age range.

Subjects who enroll in the study after the completion of the Algorithm Assessment Phase will use the closed-loop system at home for 5 nights of system use each with PLGS and Hyper Minimization active to demonstrate their ability to use the system and submit study data to the Coordinating Center.

Subjects who successfully demonstrate their ability to use the system at home as described above will be eligible for the randomized trial phase. This phase consists of use of the full system in the home for approximately 42 nights:

  • Each night the blood glucose level will be checked with the BG meter and used to perform a calibration of the CGM. This calibration must occur no more than 90 minutes prior to activation of the system. NOTE: Subjects will be instructed to calibrate the CGM per manufacturer guidelines.
  • Then the system will be activated, linking the CGM and insulin pump to the computer at the bedside.
  • A randomization schedule on the laptop will be used to determine whether the system will run in PLGS+Hyper Minimization mode or PLGS-only.

    • Subjects will be blinded as to whether the system is running in PLGS+Hyper Minimization mode or PLGS-only.
    • There will not be an alarm if the pump shuts off or if automated insulin dosing occurs. The CGM alarm will be set to 60 mg/dL (3.3 mmol/L). When a CGM alarm occurs, the subject will be asked to measure the blood glucose with a BG meter, if he/she is aware of the alarm.
    • The time period for outcome assessment each night will be from the time the system is activated until it is turned off in the morning.
    • Pump shut off, when it occurs, will be for up to 120 minutes in a 150-minute period, and no more than 180 minutes for the entire night. Multiple instances of pump suspension can occur if there are recurrent predictions of hypoglycemia during the night.
  • Small correction boluses of insulin will be delivered when the system predicts that hyperglycemia above a pre-set threshold will occur, with insulin-on-board constraints and cumulative delivery limits to minimize the likelihood of excessive insulin delivery.
  • Subjects will be asked to check blood glucose with the study BG meter each morning prior to breakfast and enter the results using the controller software interface. The subject will be instructed to contact the study physician if the morning blood glucose value is \<60 mg/dl (3.3 mmol/L) or >300 mg/dl (16.7 mmol/L). Monitoring processes will ensure that the subject can be contacted if these values are not reported as required or are out of range.
  • Subjects will be asked to record all overnight carbohydrate intake using the controller software interface.
  • Subjects will be asked to perform periodic CGM data uploads using the controller software interface. Monitoring processes will ensure that the subject can be contacted if these uploads do not occur as required, or if review of an upload reveals any extreme, prolonged episodes of hypoglycemia or hyperglycemia, or elevated morning blood glucose values.

Once approximately 200 nights of randomized clinical trial phase data are available, the study DSMB will perform another data review to determine whether it is safe to continue the study. Subjects already using the study system at home will continue to use it during the DSMB review process, but no additional subjects will begin home use of the system until the DSMB review is complete.

Upon completion of the study, subjects as well as study clinicians will be asked to complete a human factors usability questionnaire regarding use of the study system.

There will be a follow-up (optional) extension phase for subjects who exhibit safe and competent use of the system at home. They may be given the option to continue home use of the system for up to 56 days to assess whether data-driven, subject-level customization of algorithm parameters improves glycemic outcomes compared with generic algorithm parameters that are identical for each subject.

03

Conditions studied

  • Type 1 Diabetes
  • Hypoglycemia
  • Hyperglycemia
  • Artificial Pancreas
04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year and an insulin infusion pump for at least 6 months The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.
  2. Age 6.0 to \<15.0 years
  3. \< 10.0%

    • Measured with DCA2000 or equivalent device for assessing eligibility
    • HbA1c measurements performed as part of usual clinical care within 2 weeks prior to obtaining for participation in the trial may be used.
  4. Uninterrupted internet access while study system is being used overnight and for upload of study data in the morning
  5. Living with a family member/guardian ("companion") committed to participating in all study activities, and being present and available to provide assistance when the system is being used at night
  6. An understanding of and willingness to follow the protocol and sign the informed consent

Exclusion criteria

Exclusion Criteria:

  1. Diabetic ketoacidosis in the past 6 months
  2. Hypoglycemic seizure or loss of consciousness in the past 6 months
  3. History of seizure disorder (except for hypoglycemic seizure)
  4. History of any heart disease including coronary artery disease, heart failure, or arrhythmias
  5. Cystic fibrosis
  6. Current use of oral/inhaled , beta-blockers or other medications, which in the judgment of the investigator would be a to participation in the study.
  7. History of ongoing renal disease (other than microalbuminuria). Creatinine level must have been obtained within the last year if subject has diabetes of >10 years duration. If creatinine is > 1.5 mg/dL (132 µmol/L), the subject is excluded.
  8. Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:

    • Inpatient psychiatric treatment in the past 6 months
    • Uncontrolled adrenal disorder
    • Abuse of alcohol
  9. Pregnancy (Negative urine pregnancy test required for females who have experienced menarche as well as agreement from subject and parent/guardian to use a form of to prevent pregnancy while participant is in the study. Subjects who become pregnant will be discontinued from the study)
  10. Liver disease as defined by an greater than 3 times the
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Active comparator
    Hyperglycemia Minimization Algorithm

    The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.

    Device: Hyperglycemia Minimization Algorithm

  • No intervention
    Predictive Low Glucose Suspend

    The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.

Interventions

  • DeviceHyperglycemia Minimization Algorithm

    The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.

06

What researchers measure

Primary outcomes

  1. Percent Time 70-<180mg/dL Per Night Over 42 Nights

    A single percentage calculated for each subject by pooling all CGM readings from the PLSG+HM nights and PLGS-only nights for the same subject. All CGM readings regardless of the amount of data will be weighted equally in the pooled percentage regardless of how they distribute across nights.

    Time frame: 42 nights

Secondary outcomes

  1. Mean Overnight Sensor Glucose

    Time frame: Up to 42 nights

  2. Glucose Standard Deviation and Coefficient of Variation

    Time frame: Up to 42 nights

  3. Percent of Time <50 mg/dl (2.8 mmol/L) Per Night Over 42 Nights

    Time frame: 42 nights

  4. Percent Time <60 mg/dl (3.3 mmol/L) Per Night Over 42 Nights

    Time frame: 42 nights

  5. Percent Time <70 mg/dl (3.9 mmol/L) Per Night Over 42 Nights

    Time frame: 42 nights

  6. Percent Time >180 mg/dl (10.0 mmol/L) Per Night Over 42 Nights

    Time frame: 42 nights

07

Results

Posted Oct 15, 2026
Limitations and caveats
The AID system did not have an adaptive component in that the algorithm did not "learn" day-to-day based on previous data. Another potential limitation is that participants were remotely monitored overnight by study staff and parents were contacted for prolonged hypoglycemia.

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started35
Completed 23 nights with plgs+hyper minimization mode28
Completed 23 nights plgs only28
Completed28
Not completed7
Withdrew: Hba1c screening failure1
Withdrew: Schedule conflict4
Withdrew: Sensor performance2

Outcome measures

PrimaryPercent Time 70-<180mg/dL Per Night Over 42 Nights

A single percentage calculated for each subject by pooling all CGM readings from the PLSG+HM nights and PLGS-only nights for the same subject. All CGM readings regardless of the amount of data will be weighted equally in the pooled percentage regardless of how they distribute across nights.

Time frame:
42 nights
Reported as:
Mean · percentage of time
Percent Time 70-<180mg/dL Per Night Over 42 Nights
percentage of timeAll Participants
PLGS+Hyper Minimization mode76 ± 9
PLGS-only mode66 ± 11
SecondaryMean Overnight Sensor Glucose
Time frame:
Up to 42 nights
Reported as:
Mean · mg/dL
Mean Overnight Sensor Glucose
mg/dLAll Participants
PLGS+Hyper Minimization mode147 ± 13
PLGS-only mode160 ± 15
SecondaryGlucose Standard Deviation and Coefficient of Variation
Time frame:
Up to 42 nights
Reported as:
Median · mg/dL
Glucose Standard Deviation and Coefficient of Variation
mg/dLAll Participants
PLGS+Hyper Minimization mode46 (41 to 55)
PLGS-only mode55 (48 to 63)
SecondaryPercent of Time <50 mg/dl (2.8 mmol/L) Per Night Over 42 Nights
Time frame:
42 nights
Reported as:
Median · percentage of time
Percent of Time <50 mg/dl (2.8 mmol/L) Per Night Over 42 Nights
percentage of timeAll Participants
PLGS+Hyper Minimization mode0.2 (0.0 to 0.3)
PLGS-only mode0.1 (0.0 to 0.4)
SecondaryPercent Time <60 mg/dl (3.3 mmol/L) Per Night Over 42 Nights
Time frame:
42 nights
Reported as:
Median · percentage of time
Percent Time <60 mg/dl (3.3 mmol/L) Per Night Over 42 Nights
percentage of timeAll Participants
PLGS+Hyper Minimization mode0.6 (0.2 to 1.1)
PLGS-only mode0.7 (0.2 to 0.9)
SecondaryPercent Time <70 mg/dl (3.9 mmol/L) Per Night Over 42 Nights
Time frame:
42 nights
Reported as:
Median · percentage of time
Percent Time <70 mg/dl (3.9 mmol/L) Per Night Over 42 Nights
percentage of timeAll Participants
PLGS+Hyper Minimization mode1.8 (1.0 to 2.9)
PLGS-only mode1.8 (0.9 to 2.6)
SecondaryPercent Time >180 mg/dl (10.0 mmol/L) Per Night Over 42 Nights
Time frame:
42 nights
Reported as:
Median · percentage of time
Percent Time >180 mg/dl (10.0 mmol/L) Per Night Over 42 Nights
percentage of timeAll Participants
PLGS+Hyper Minimization mode21 (15 to 30)
PLGS-only mode30 (22 to 40)

Adverse events

Collected over 42 nights. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants0/28 (0%)0/28 (0%)0/28 (0%)

Baseline characteristics

35 participants enrolled, 7 withdrew prior to randomization; HbA1c screen failure, N=1, scheduling conflict, N=4, sensor performance, N=2

Age, Customized
Age, Customized(years)All Participants
Median12 (6 to 14)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female15
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
White Non-Hispanic22
Hispanic2
Pacific Islander1
Asian1
Black1
More than one race1
Diabetes Duration
Diabetes Duration(years)All Participants
Median4 (3 to 7)
Body-Mass Index
Body-Mass Index(kg/m^2")All Participants
Median17.8 (16.6 to 19.8)
HbA1c
HbA1c(percent)All Participants
Median7.9 (7.2 to 8.8)
08

Study locations

2 sites
  • Stanford University
    Stanford, California 94305, United States
  • Barbara Davis Center for Childhood Diabetes
    Aurora, Colorado 80045, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Mar 2017, 10 months.

Results were first posted in Oct 2026, 9 years 7 months after primary completion.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 10 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2016
First posted
Mar 22, 2016
StartActual
May 2016
Primary completionActual
Mar 2017
CompletionActual
May 2017
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Comparison of percent time in range overnight between the two treatment armsNow Percent Time 70-<180mg/dL Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
Oct 15, 2026
Documents
Secondary outcomes
6 edited, 16 removed
What changed in the outcomes
  • EditedMean overnight sensor glucoseOvernight Sensor GlucoseTime frame: Up to 42 nights
  • EditedGlucose standard deviationStandard Deviation and coefficientCoefficient of variationVariationTime frame: Up to 42 nights
  • EditedPercent of sensor measurements below Time <50 mg/dl (2.8 mmol/L) Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
  • EditedPercent of sensor measurements below Time <60 mg/dl (3.3 mmol/L) Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
  • EditedPercent of sensor measurements below Time <70 mg/dl (3.9 mmol/L) Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
  • EditedArea under the curve 70Percent Time >180 mg/dl (310.90 mmol/L) Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
  • RemovedLow blood glucose indexTime frame: Up to 42 nights
  • RemovedPercent of sensor measurements above 180 mg/dl (10.0 mmol/L)Time frame: Up to 42 nights
  • RemovedPercent of sensor measurements above 250 mg/dl (13.9 mmol/L)Time frame: Up to 42 nights
  • RemovedPercent of sensor measurements above 300 mg/dl (16.7 mmol/L)Time frame: Up to 42 nights
  • RemovedArea under the curve 180 mg/dl (10.0 mmol/L)Time frame: Up to 42 nights
  • RemovedHigh blood glucose indexTime frame: Up to 42 nights
  • RemovedPercent of sensor measurements between 70 mg/dl (3.9 mmol/L)Time frame: Up to 42 nights
  • RemovedPercent of sensor measurements between 140 mg/dl (7.8 mmol/L)Time frame: Up to 42 nights
  • RemovedPercentage of nights with events of sensor glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), and 70 mg/dl (3.9 mmol/L) continuously for more than 0, 10, 25, 30, 60, and 120 minutesTime frame: Up to 42 nights
  • RemovedPercentage of nights with events of sensor glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), and 70 mg/dl (3.9 mmol/L) cumulatively for more than 30, 60, 120, and 180 minutesTime frame: Up to 42 nights
  • RemovedPercentage of nights with events of sensor glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) continuously for more than 0, 30, 60, and 120 minutesTime frame: Up to 42 nights
  • RemovedPercentage of nights with events of sensor glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) cumulatively for more than 60, 120, and 180 minutesTime frame: Up to 42 nights
  • RemovedMean morning blood glucose (subject-level data) and percent of morning with blood glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), 70 mg/dl (3.9 mmol/L) (night-level data)Time frame: Up to 42 nights
  • RemovedMean morning blood glucose (subject-level data) and percent of morning with blood glucose between 70 mg/dl (3.9 mmol/L) and 180 mg/dl (10.0 mmol/L) (night-level data)Time frame: Up to 42 nights
  • RemovedMean morning blood glucose (subject-level data) and percent of morning with blood glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) (night-level data)Time frame: Up to 42 nights
  • RemovedAmount of total (manual, automatic, combined) and insulin bolusesTime frame: Up to 42 nights
Oct 15, 2026
Design
Phase 2→Not applicable
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Comparison of percent time in range overnight between the two treatment armsNow Percent Time 70-<180mg/dL Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
    Secondary outcomes 6 edited, 16 removed
    What changed in the outcomes
    • EditedMean overnight sensor glucoseOvernight Sensor GlucoseTime frame: Up to 42 nights
    • EditedGlucose standard deviationStandard Deviation and coefficientCoefficient of variationVariationTime frame: Up to 42 nights
    • EditedPercent of sensor measurements below Time <50 mg/dl (2.8 mmol/L) Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
    • EditedPercent of sensor measurements below Time <60 mg/dl (3.3 mmol/L) Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
    • EditedPercent of sensor measurements below Time <70 mg/dl (3.9 mmol/L) Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
    • EditedArea under the curve 70Percent Time >180 mg/dl (310.90 mmol/L) Per Night Over 42 NightsTime frame: Up to 42 nights → 42 nights
    • RemovedLow blood glucose indexTime frame: Up to 42 nights
    • RemovedPercent of sensor measurements above 180 mg/dl (10.0 mmol/L)Time frame: Up to 42 nights
    • RemovedPercent of sensor measurements above 250 mg/dl (13.9 mmol/L)Time frame: Up to 42 nights
    • RemovedPercent of sensor measurements above 300 mg/dl (16.7 mmol/L)Time frame: Up to 42 nights
    • RemovedArea under the curve 180 mg/dl (10.0 mmol/L)Time frame: Up to 42 nights
    • RemovedHigh blood glucose indexTime frame: Up to 42 nights
    • RemovedPercent of sensor measurements between 70 mg/dl (3.9 mmol/L)Time frame: Up to 42 nights
    • RemovedPercent of sensor measurements between 140 mg/dl (7.8 mmol/L)Time frame: Up to 42 nights
    • RemovedPercentage of nights with events of sensor glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), and 70 mg/dl (3.9 mmol/L) continuously for more than 0, 10, 25, 30, 60, and 120 minutesTime frame: Up to 42 nights
    • RemovedPercentage of nights with events of sensor glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), and 70 mg/dl (3.9 mmol/L) cumulatively for more than 30, 60, 120, and 180 minutesTime frame: Up to 42 nights
    • RemovedPercentage of nights with events of sensor glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) continuously for more than 0, 30, 60, and 120 minutesTime frame: Up to 42 nights
    • RemovedPercentage of nights with events of sensor glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) cumulatively for more than 60, 120, and 180 minutesTime frame: Up to 42 nights
    • RemovedMean morning blood glucose (subject-level data) and percent of morning with blood glucose below 50 mg/dl (2.8 mmol/L), 60 mg/dl (3.3 mmol/L), 70 mg/dl (3.9 mmol/L) (night-level data)Time frame: Up to 42 nights
    • RemovedMean morning blood glucose (subject-level data) and percent of morning with blood glucose between 70 mg/dl (3.9 mmol/L) and 180 mg/dl (10.0 mmol/L) (night-level data)Time frame: Up to 42 nights
    • RemovedMean morning blood glucose (subject-level data) and percent of morning with blood glucose above 180 mg/dl (10.0 mmol/L), 250 mg/dl (13.9 mmol/L), and 300 mg/dl (16.7 mmol/L) (night-level data)Time frame: Up to 42 nights
    • RemovedAmount of total (manual, automatic, combined) and insulin bolusesTime frame: Up to 42 nights
    Design Phase 2→Not applicable
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02714972
Responsible party
Sponsor
First posted
Mar 22, 2016
Start date
May 2016
Primary completion
Mar 2017
Completion
May 2017
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Bruce A Buckingham, MD
study chair · Stanford University
John W Lum, MS
study director · Jaeb Center for Health Research
Roy Beck, MD, PhD
principal investigator · Jaeb Center for Health Research

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion